Influences of Vitamin A on Vaccine Immunogenicity and Efficacy

Rhiannon R. Penkert 1, Hannah M. Rowe 1, Sherri L. Surman 1, Robert E. Sealy 1, Jason Rosch 1 and Julia L. Hurwitz 1,2*

1 Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN, United States, 2 Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN, United States

Vitamin A deficiencies and insufficiencies are widespread in developing countries, and may be gaining prevalence in industrialized nations. To combat vitamin A deficiency (VAD), the World Health Organization (WHO) recommends high-dose vitamin A supplementation (VAS) in children 6–59 months of age in locations where VAD is endemic. This practice has significantly reduced all-cause death and diarrhea-related mortalities in children, and may have in some cases improved immune responses toward pediatric vaccines. However, VAS studies have yielded conflicting results, perhaps due to influences of baseline vitamin A levels on VAS efficacy, and due to cross-regulation between vitamin A and related nuclear hormones. Here we provide a brief review of previous pre-clinical and clinical data, showing how VAD and VAS affect immune responses, vaccines, and infectious diseases. We additionally present new results from a VAD mouse model. We found that when VAS was administered to VAD mice at the time of vaccination with a pneumococcal vaccine (Prevnar-13), pneumococcus (T4)-specific antibodies were significantly improved. Preliminary data further showed that after challenge with Streptococcus pneumoniae, all mice that had received VAS at the time of vaccination survived. This was a significant improvement compared to vaccination without VAS. Data encourage renewed attention to vitamin A levels, both in developed and developing countries, to assist interpretation of data from vaccine research and to improve the success of vaccine programs.

Keywords: vitamin A, pneumococcus, supplementation, vaccines, immune response

INTRODUCTION

Vitamin A deficiency (VAD) adversely affects children and adults worldwide. Today, the World Health Organization (WHO) estimates that 250 million preschool children suffer from VAD, with the highest frequencies among low-income areas of Africa and South-East Asia [http://www.who.int (accessed March 01, 2019)]. Infectious diseases, particularly respiratory and diarrheal diseases, occur at increased frequencies (at least 2:1) among populations with VAD compared to vitamin-replete populations (1).

The global burden of VAD and its effects on populations in developing countries are well known, but much less well appreciated are incidences of VAD and vitamin insufficiencies in the developed world (2–5). In Memphis, TN, we tested influenza virus-infected children and their household contacts for retinol binding protein (RBP) as a surrogate for vitamin A (6), and found that 13 of 21 individuals were either vitamin A insufficient or deficient (5). We found that both infected and uninfected study participants exhibited low RBP levels. Low RBP can be a consequence of illness (7), but also reflects conditions of malnutrition when individuals in low-income families...
have limited access to nutrient-rich foods (8–10). Whereas, infants in the United States may receive government-funded, vitamin-fortified formulas, comparable support is not given to older children (11). Instead, diets for older children and adults may be calorie-dense and nutrient-poor. As is the case in developing countries, vitamin insufficiencies and deficiencies in the developed world correlate with weakened immune responses and poor outcomes upon hospitalization for infectious disease (2, 4). Unlike the situation in the developing world, individuals in the United States are usually assumed to be vitamin A-replete. Malnutrition may therefore go unnoticed.

**Vitamin A Requirements, Metabolism, and Trafficking**

Vitamin A is acquired from the diet in the form of retinoids (preformed vitamin A) or carotenoids (provitamin A). Retinoids include retinol or retinyl esters from animal sources, whereas carotenoids include beta-carotenes from plants. The recommended daily allowance (RDA) for vitamin A is dependent on age and sex. The Office of Dietary supplements (ODS) at the National Institutes of Health (NIH) currently recommends an RDA ranging from 300 to 600 µg retinol acid equivalents (RAE) for young children. For individuals aged ≥14 years, RDAs are 700 µg RAE for non-pregnant females and 900 µg RAE for males (1 IU retinol = 0.3 microgram RAE) [https://ods.od.nih.gov (accessed March 01, 2019)]. A blood level of <0.7 µM retinol is considered vitamin “deficient” or “inadequate,” and levels between 0.7 and 1.05 µM retinol are considered “insufficient” or “marginal” for some biological functions (12).

Vitamin A is generally stored in the liver as esters, but can also be found in extra-hepatic sites such as lung, intestine, kidney, and adipose tissue (13, 14). Retinol is the most common vitamin A metabolite in the blood and typically circulates in a complex bound to RBP with a 1:1 molar ratio. Retinol-bound RBP (holo-RBP) is, in turn, often bound to transthyretin, a common serum transport protein (15, 16). Retinoids can also be transported by chylomicrons or chylomicron remnants in lymph and blood (14, 17). Intracellularly, retinol is converted by retinol dehydrogenases (RDH, ubiquitous enzymes) to retinal, and then by retinaldehyde dehydrogenases (RALDH, e.g., ALDH1A) in select tissues to retinoic acid (RA) (18–21). RA is the vitamin A metabolite best known for its ability to regulate innate and adaptive immune cell function, proliferation, and survival. Importantly, metabolism and trafficking of vitamin A, and consequent effects on the immune system, can be influenced by genetic backgrounds, diets, conditions of malabsorption, and obesity (22). In the case of obesity, animal experiments suggest that vitamin A may be deficient in tissues such as the lung, even when levels in blood appear to be replete (23).

**Regulatory Functions of Vitamin A**

Virtually every mammalian cell, including epithelial and immune cells, is affected by vitamin A (7, 24–34). Vitamin A is perhaps best known for its regulation of gene transcription. RA is a nuclear hormone that binds nuclear hormone receptors including the retinoic acid receptor (RAR) and the peroxisome proliferator-activated receptor (PPARβ/δ) (35, 36). Receptors, in turn, bind DNA and serve as transcription factors to enhance or inhibit gene expression (27). Multiple isoforms exist for RAR [e.g., RARα, β, and γ (37)], and each protein can bind to the retinoid X receptor (RXR) in a heterodimeric complex (27, 38).

Receptors are promiscuous in binding to their ligands and to DNA. The RAR-RXR heterodimer will often bind two half-site sequences, known as retinoic acid response elements (RAREs), separated by a short spacer in the DNA (27, 39–44). RAREs have a consensus sequence of 5′-(A/G)G(G/T)TCA-3′, though receptors can be bound to non-consensus DNA sites as well. The exact sequence and spacer length (typically zero to eight bases) can alter binding affinity. Additionally, receptors can bind indirectly to DNA by tethering to other DNA-bound factors. Cross-regulation between vitamin A and related nuclear hormones (e.g., vitamin D, thyroid hormone, or sex hormones) may occur, because nuclear hormone receptors can compete for binding to ligands, co-receptors, and DNA (27, 40, 45–48).

RAREs are found throughout the genome, often within gene promoters or enhancers. Notably, hotspots for RARE have been identified in switch sites of the immunoglobulin heavy chain locus, positions instrumental in class switch recombination (CSR) (49). The potential binding of nuclear hormone receptors to switch sites and regulatory elements in immunoglobulin and T cell receptor (TCR) loci predicts a direct mechanism by which vitamin A may modulate lymphocyte function (49–52).

Adding to the complexity of vitamin A functions are the extra-nuclear activities. Vitamins bind a complex array of escort proteins at the cell membrane and in extra-nuclear compartments. Each of these interactions can initiate or modulate cell signaling (53, 54).

**Vitamin A and Immune Activities in vitro and in Small Animals**

Essentially all cells of the immune system including innate cells, B cells, and T cells, are affected by vitamin A (31, 55–59). Research animals with VAD generate poor antibody responses to many pathogens including parainfluenza virus and influenza virus (34, 59–61). VAS, when administered either orally or intranasally, can correct responses when given at the time of vaccination (33, 59, 60, 62).

In vitro, vitamin A has been shown to upregulate IgA production by B cells (18, 63, 64), and skew T cell phenotypes toward Treg rather than Th17 populations (65–70), but in vivo, outcomes are less predictable (71). For example, whereas VAD cells may yield poor Treg activities in a tissue culture setting indicating a predisposition for heightened immune responses (65–68), Tregs are found at equal or greater frequencies in tissues of VAD mice compared to controls following a respiratory virus.
infection (32). Furthermore, VAD mice exhibit relatively poor pathogen-specific T cell responses in vivo. In studies of influenza virus and parainfluenza virus infections, there are only weak virus-specific CD8+ T cell responses in the lower respiratory tract (LRT) of VAD mice (26). Responding CD8+ T cells in VAD and vitamin A+D deficient (VAD+VDD) mice express high levels of membrane CD103 (the αE subunit of αEβ7, an e-cadherin receptor). Possibly, the poor recruitment of CD8+ T cells to the LRT is because LRT tissues express relatively low levels of e-cadherin, and CD103+ cells home preferentially to other sites (26). When VAD+VDD mice receive VAS (with or without supplemental vitamin D), CD103 levels on virus-specific CD8+ T cells are reduced, and the percentages of CD4+ and CD8+ T cells in the LRT are improved (72). As another example of the complex influences of vitamin A on immune responses, we find that serum antibody isotype distributions differ between VAD and control animals, but patterns are dependent on the animal’s background and sex (50). As a last example, some studies show that VAD biases the immune response toward a Th1 profile and that high levels of vitamin A bias the response toward a Th2 profile (68, 73, 74). Nonetheless, outcomes are again dependent on cell targets, environment, and activation state (25). Both Th1 and Th2 cytokine responses are evident in VAD mice, and VAD animals express higher levels of Th1 and Th2 cytokines compared to controls at late stages following a respiratory virus infection, presumably as a consequence of poor virus clearance (32).

Vitamin A additionally influences epithelial cells and innate immune cells associated with mucosal surfaces. Dendritic cells of the intestine and epithelial cells of the respiratory tract each express the ALDH1A enzymes required for conversion of retinaldehyde to the end-metabolite RA (18, 26, 29). These unique attributes of mucosal tissues help explain why VAS assists immune responses when applied either orally or intranasally (33, 62).

Due to the plethora of immune cell and barrier cell requirements for vitamin A, it is not surprising that VAD associates with poor immune responses to vaccines, and that VAS can reverse these weaknesses when given at the time of vaccination (33, 34, 59–62). One vaccine that deserves continued study in the context of VAD and VAS is Prevnar-13. It is estimated that worldwide pneumococcus kills close to 1 million children under the age of 5 each year (75, 76). Prevnar-13 can protect against these mortalities (77, 78), but the vaccine-induced immune response is not always protective. We suggest that attention to, and correction of, low vitamin levels in Prevnar-13 vaccine recipients may improve vaccine success. Previous studies have shown that VAD inhibits responses both to individual pneumococcus antigens and to Prevnar-13 in mice (59, 61, 79–81). Here, we extend findings to show that VAS improves the immunogenicity and protective capacity of Prevnar-13 in VAD and control animals.

**MATERIALS AND METHODS**

**Mice and Vaccinations**

Experiments were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at St. Jude Children’s Research Hospital (St. Jude). St. Jude follows the standards of the Animal Welfare Act and the document entitled “Principles for the Use of Animals and Guide for the Care and Use of Laboratory Animals.”

To produce VAD mice, pregnant C57BL/6 (H2-b) mice were purchased from Jackson Laboratories (Bar harbor, ME). Mice were placed on either a control or VAD diet upon their arrival in the animal facility at St. Jude (days 4–5 gestation). VAD (cat. no. 5WA2, Test Diets) and control (cat. no. 5W9M) diets differed only in vitamin A content, containing either 0 or 15 IU/g vitamin A palmitate, respectively. Mothers and progeny remained on their assigned diets. Experiments were begun when progeny reached adulthood. These adult mice were vaccinated with 2 doses of Prevnar-13 (PCV, Wyeth Pharmaceuticals Inc.) with 3 weeks intervals. Vaccine was diluted 1:40 in PBS and 100 µL of PCV was administered intraperitoneally (IP). Immediately prior to each vaccination, mice received either 600 IU vitamin A (from Interplexus Inc., Kent, WA) or PBS by oral gavage (100 µL).

**Antibody Measurements by ELISA**

Animals were bled 10–14 days after boosting. ELISA plates were coated with 50 µL/well of 5 µg/mL T4 polysaccharide (from American Type Culture Collection, ATCC, Manassas, VA) in PBS using an Integra Viaflo384 robot (Integra Biosciences, Hudson, NH) and incubated overnight at 4°C. Plates were then washed 3x with PBS using an Aquamax 4000 plate washer (Molecular Devices, San Jose, CA). Block was 1% BSA in PBS (200 µL/well) added robotically and incubated overnight at 4°C. Mouse serum samples were diluted 1:500 in dilution buffer (1% BSA + 0.05% Tween in PBS). Block was removed and samples were added to plates (50 µL/well) and incubated overnight at 4°C. Plates were then washed 3x with PBS +0.05% Tween using the plate washer. Developing antibodies were added robotically (100 µL/well). These were anti-mouse IgM (cat. no. 1020-04; Southern Biotech, Birmingham, AL), anti-mouse IgG1 (cat. no. 1070-04; Southern Biotech), or anti-mouse IgG3 (cat. no. 1100-04; Southern Biotech), each diluted 1:1000 in dilution buffer. Plates were incubated 1 h at room temperature and then washed 3x with PBS +0.05% Tween using the plate washer. Substrate (1 mg/mL of pNPP in diethanolamine buffer; 100 µL/well) was added robotically to plates. Plates were developed for 5–15 min and read at 405 nm on a VersaMax Tunable Microplate Reader (Molecular Devices). Statistical comparisons were made using Mann Whitney tests and GraphPad Prism software (**p < 0.05, ***p < 0.001**).

**Challenges Post-vaccination**

To prepare bacteria for challenge experiments, S. pneumoniae strain TIGR4 (serotype 4) was inoculated from a glycerol stock onto a Tryptic Soy Agar plate (GranCult, Millipore, Burlington, MA) and 20 µL of pNPP in diethanolamine buffer; 100 µL/well) added robotically and incubated overnight at 4°C. Mouse serum samples were diluted 1:500 in dilution buffer (1% BSA + 0.05% Tween in PBS). Block was removed and samples were added to plates (50 µL/well) and incubated overnight at 4°C. Plates were then washed 3x with PBS +0.05% Tween using the plate washer. Substrate (1 mg/mL of pNPP in diethanolamine buffer; 100 µL/well) was added robotically to plates. Plates were developed for 5–15 min and read at 405 nm on a VersaMax Tunable Microplate Reader (Molecular Devices). Statistical comparisons were made using Mann Whitney tests and GraphPad Prism software (**p < 0.05, ***p < 0.001**).
FIGURE 1 | VAS and T4 polysaccharide-specific immune responses. Results from T4 ELISAs are shown for VAD (top row) and vitamin A-replete control (bottom row) mice. Separate ELISAs were conducted to measure T4-specific IgM, IgG1, and IgG3 antibodies. Statistical comparisons were made using Mann Whitney tests and GraphPad Prism software (*p < 0.05, **p < 0.01, ***p < 0.001). IgM levels (for VAD mice), and IgG1 levels (for VAD and control mice), but not IgG3 levels, were significantly improved with VAS.

To challenge mice, 2 weeks after the vaccine boost, animals were sedated with 3% isoflurane. They were then inoculated intranasally with 5 × 10⁵ CFU S. pneumoniae in 100 µL PBS. To collect and titer lungs, 24 h after infections groups of animals were euthanized by CO₂ asphyxiation and cervical dislocation. Lungs were removed, washed twice in ∼1 mL of PBS and then placed in 0.5 mL PBS. Lungs were then pulverized with a mechanical tissue grinder. Following emulsification, lungs were spun for 5 min at 300 g to pellet debris. Supernatants from the lung homogenates were collected and serially diluted 1:10 in PBS five times. From each dilution, 10 µL were plated on a Tryptic Soy Agar plate (GranCult, Millipore) supplemented with 3% sheep blood (Lampire Biological Laboratory) and 20 µg/mL neomycin. Plates were incubated overnight at 37°C. Colonies were counted and Excel software was used to calculate titers. Separate groups of animals were infected as described above, monitored for signs of symptomatic infection, and euthanized when moribund.

RESULTS
Vaccine studies were conducted with male and female mice (either VAD mice or vitamin-replete controls) that were given two successive IP immunizations, separated by 3 week intervals, with the Prevnar-13 vaccine. Mice received either 600 IU of vitamin A as retinyl palmitate by oral gavage or phosphate buffered saline (PBS) at the time of vaccination. Antibody responses were measured 10–14 days after the second vaccine dose. ELISAs were conducted to examine antibodies specific for the type 4 (T4) component of the vaccine. As shown...
FIGURE 2 | VAS with vaccination improves survival after challenge. Challenge results are shown for VAD (top row) and vitamin-replete control (bottom row) mice. CFU per lung were measured 24 h after challenge (left). In separate groups of mice, survival was monitored (right). Animals were sacrificed when moribund. Survival curves were compared using GraphPad Prism software (*p < 0.05, **p < 0.01).

in Figure 1, there was significant improvement of T4-specific antibodies, including IgM and IgG1 isotypes in VAD mice and IgG1 in control mice when VAS was used. IgG3 levels were not significantly changed. Results were reminiscent of previous studies in rats using bacterial antigens and retinol treatments (79–82).

In a preliminary set of experiments, vaccinated animals were also challenged with a high-dose ($5 \times 10^5$ colony forming units, CFU) of pneumococcus (*Streptococcus pneumoniae* strain TIGR4 [serotype 4]). At this dose, >90% of unvaccinated VAD and vitamin-replete control mice developed an infection, and the dose was 100% lethal in unvaccinated VAD animals (Figure 2). After 24 h, groups of 8–10 mice were sacrificed to measure lung titers. As shown, there were trends toward lower CFU in both VAD and control animals that received VAS at the time of vaccination. A separate set of mice were tested for survival post-challenge. There were significant improvements in survival for VAD and control animals that received VAS at the time of vaccination compared to unsupplemented, vaccinated animals. In fact, all animals that received VAS at the time of vaccination, regardless of original vitamin A status, survived.

**DISCUSSION**

We have shown that VAS supports improvements in the immunogenicity of Prevnar-13 in VAD and control mice. With a preliminary study, we also showed that when VAS was given coincident with vaccination, protection against a subsequent challenge with *S. pneumoniae* was improved. Based on these promising results, we are now initiating a randomized clinical study to test the effects of VAS among Memphian children vaccinated with Prevnar-13 (clinicaltrials.gov, PCVIT NCT03859687).

**Previous Research on VAD and VAS in Humans**

Public health organizations strive to improve dietary nutrition worldwide, but this goal depends on delivering vitamin-rich foods to all populations, a formidable task. For infants in countries where VAD is known to be endemic, the WHO has supported high-dose VAS programs (83). Children often receive 100,000 IU vitamin A between the ages of 6–11 months and 200,000 IU every 4–6 months between the ages of 12–59 months (84). Research analyses of VAS have yielded positive results in countries where VAD is frequent. In meta-analyses of clinical trials, VAS was shown to reduce deaths by 12–24%, and in isolated studies, reductions of 35–50% were observed (1, 85–92). VAS reduced morbidities due to infectious diseases, including measles, *Plasmodium falciparum*, and HIV (93–96). VAS benefits were also observed when antibody responses were measured, including those to vaccination (97, 98). Some studies have shown
improved responses to the measles and tetanus toxoid (TT) vaccines following VAS (99–101).

Unfortunately, despite the positive influences described above, results from clinical VAS research have been inconsistent. VAS studies have often failed to show benefit, and have in some cases demonstrated risk. As an example, Malaba et al. did not observe an effect of VAS on infant mortality among children born to HIV-negative mothers with apparently adequate baseline vitamin A levels (102). There have also been reports of increased mother to child transmission (MTCT) of HIV in the context of VAS (103, 104). Additional noted risks of high-dose VAS were fontanelle bulging in infants (105, 106) and bone density loss [possibly due to cross-inhibition between related nuclear hormones, in this case vitamins A and D (107, 108)].

VAS studies in the context of vaccine programs have also yielded conflicting data (97, 109, 110). Brown et al. for example, showed no improvements by VAS on TT vaccinations (110) and a study of HIV-infected individuals showed no improvements by VAS on influenza virus vaccinations (111). A study by Semba et al. showed a negative influence of VAS on responses to the measles vaccine in 6 month old infants (112), unlike the situation for older infants (100, 113, 114). Explanations for differences in VAS efficacy among clinical studies have addressed effects of age, maternal antibodies, serum antibody levels, and serum vitamin levels, but a consensus has not been reached (90).

The contradictory results described above have encouraged the scientific community to question indiscriminate use of VAS, particularly in communities where nutrition has improved and where many children are vitamin replete (97, 106, 115). Suggestions are made to redirect efforts toward the use of low-dose VAS and/or toward support of improved diets (116).

One clear weakness in past clinical research is that comprehensive baseline vitamin levels of study participants for vitamin A and the related, cross-regulatory nuclear hormone vitamin D (47, 117–119) were rarely reported. Instead, vitamin status has often been predicted based on previous population studies (e.g., frequencies of xerophthalmia). This strategy does not address changing diets within communities or individual differences among study participants. Currently, perceptions of VAD frequencies may thus be falsely high for certain developing countries and falsely low for the developed world. The situation differs dramatically from research studies in small animals, wherein host backgrounds and diets are homogeneous and test animals differ from controls by a single defined variable. A full comprehension of how VAS differentially affects humans with replete, insufficient, or deficient vitamin A and D levels remains elusive.

A long-term solution to VAD in humans will require close attention to host characteristics, particularly baseline vitamin A and D levels (52). Improvements in diets should be a primary focus, with VAS programs developed as a back-up solution to malnutrition. For best outcomes with VAS, programs may require customization, with modification of supplements by frequency or dose, dependent on baseline characteristics of vaccine recipients. With attention to pre-existing vitamin levels and cautious administration, VAS programs may ultimately ensure that, (i) vaccinated children and adults are vitamin A replete worldwide, (ii) toxicities are avoided, and (iii) world populations maintain robust immune responses to pathogens and vaccines.

**DATA AVAILABILITY**

All datasets generated for this study are included in the manuscript.

**AUTHOR CONTRIBUTIONS**

JH and JR contributed to experimental design, data analyses, and the writing and review of the manuscript. RP, HR, SS, and RS contributed to experimental design, performance of the experiments, data analyses, and the writing and review of the manuscript.

**FUNDING**

Funding was provided in part by NIH NCI P30 CA21765 and ALSAC.

**ACKNOWLEDGMENTS**

We thank Amy Iverson for assistance with experiments.

**REFERENCES**

1. Sommer A. Vitamin A, infectious disease, and childhood mortality: a 2 cent solution? J Infect Dis. (1993) 167:1003–7. doi: 10.1093/infectdis/167.5.1003
2. Stephens D, Jackson PL, Gutierrez Y. Subclinical vitamin A deficiency: a potentially unrecognized problem in the United States. Pediatr Nurs. (1996) 22:377–89.
3. Schall JJ, Zemel BS, Kawchak DA, Ohene-Frempong K, Stallings VA. Vitamin A status, hospitalizations, and other outcomes in young children with sickle cell disease. J Pediatr. (2004) 145:99–106. doi: 10.1016/j.jpeds.2004.03.051
4. Hurwitz JL, Jones BG, Penkert RR, Gansebom S, Sun Y, Tang L, et al. Low retinol-binding protein and vitamin D levels are associated with severe outcomes in children hospitalized with lower respiratory tract infection and respiratory syncytial virus or human metapneumovirus detection. J Pediatr. (2017) 187:323–7. doi: 10.1016/j.jpeds.2017.04.061
5. Jones BG, Oshansky CM, Bajracharya R, Tang L, Sun Y, Wong SS, et al. Retinol binding protein and vitamin D associations with serum antibody isotypes, serum influenza virus-specific neutralizing activities and airway cytokine profiles. Clin Exp Immunol. (2016) 183:239–47. doi: 10.1111/cei.12718
6. Almekinder J, Manda W, Soko D, Lan Y, Hoover DR, Semba RD. Evaluation of plasma retinol-binding protein as a surrogate measure for plasma retinol concentrations. Scand J Clin Lab Invest. (2000) 60:199–203. doi: 10.1080/003655100750044848
7. Stephens CB. Vitamin A, infection, and immune function. Annu Rev Nutr. (2001) 21:167–92. doi: 10.1146/annurev.nutr.21.1.167
8. Mui Y, Lee BY, Adam A, Kharmats AY, Budd N, Nau C, et al. Healthy versus unhealthy suppliers in food desert neighborhoods: a network analysis of corner stores’ food supplier networks. Int J Environ Res Public Health. (2015) 12:15058–74. doi: 10.3390/ijerph121214965
26. Rudraraju R, Surman SL, Jones BG, Sealy RE, Thomas PG, et al. Maternal retinoids control type 3 innate lymphoid cell development. *J Exp Med.* (2014) 32:2521–4. doi: 10.1084/jem.2012.0203

27. Evans RM, Mangelsdorf DJ. Nuclear receptors, RXR, and the big bang. *Cell* (2014) 157:255–66. doi: 10.1016/j.cell.2014.03.012

28. Chopra DP, Klinger MM, Sullivan JK. Effects of vitamin A on growth and differentiation of human tracheobronchial epithelial cell cultures in serum-free medium. *J Cell Sci.* (1989) 93:133–42.

29. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. *Nat Rev Immunol.* (2008) 8:683–98. doi: 10.1038/nri2378

30. Mora JR, von Andrian UH. Retinoic acid: an educational “vitamin elixir” for gut-seeking T cells. *Immunity.* (2004) 21:458–60. doi: 10.1016/j.immuni.2004.10.002

31. van de Pavert SA, Ferreira M, Domingues RG, Ribeiro H, Molenaar R, Moreira-Santos L, et al. Maternal retinoids control type 3 innate lymphoid cells and set the offspring immunity. *Nature.* (2014) 508:123–7. doi: 10.1038/nature13158

32. Penkert RR, Surman SL, Jones BG, Sealy RE, Vogel P, Neale G, et al. Vitamin A deficient mice exhibit increased viral antigens and enhanced cytokine/chemokine production in nasal tissues following respiratory virus infection despite the presence of FoxP3+ T cells. *Int Immunol.* (2016) 28:139–52. doi: 10.1039/ntimm/doi2004

33. Surman SL, Jones BG, Sealy RE, Rudraraju R, Hurwitz JL. Oral retinyl palmitate or retinoid acid corrects mucosal IgA responses toward an intranasal influenza virus vaccine in vitamin A deficient mice. *Vaccine.* (2014) 32:2521–4. doi: 10.1016/j.vaccine.2013.05.025

34. Surman SL, Rudraraju R, Sealy RE, Jones B, Hurwitz JL. Vitamin A deficiency disrupts vaccine-induced antibody-forming cells and the balance of IgA/IgG isotypes in the upper and lower respiratory tract. *Viral Immunol.* (2012) 25:341–4. doi: 10.1089/vim.2012.0203

35. Shaw N, Elholm M, Noy N. Retinoic acid is a high affinity selective ligand for the peroxisome proliferator-activated receptor beta/delta. *J Biol Chem.* (2003) 278:41589–92. doi: 10.1074/jbc.M300368200

36. Choi JM, Bothwell AL. The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases. *Mol Cells.* (2012) 33:217–22. doi: 10.1007/s10059-012-2297-y

37. Ghyselinck NB, Dupé V, Dierich A, Messaddeq N, Garnier JM, Rochette-Egly C, et al. Role of the retinoic acid receptor beta (RARbeta) during mouse development. *Int J Dev Biol.* (1997) 41:425–47.

38. Schug TT, Berry DC, Shaw NS, Travis SN, Noy N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. *Cell.* (2007) 129:723–33. doi: 10.1016/j.cell.2007.02.050

39. Privalsky ML. The role of corepressors in transcriptional regulation by nuclear hormone receptors. *Annu Rev Physiol.* (2004) 66:315–360. doi: 10.1146/annurev.physiol.66.030202.155556

40. Lee S, Privalsky ML. Heterodimers of retinoic acid receptors and thyroid hormone receptors display unique combinatorial regulatory properties. *Mol Endocrinol.* (2005) 19:863–78. doi: 10.1210/me.2004-0210

41. Boergesen M, Federsen TÅ, Goss B, van Heeringen S, Hagenbek D, Bindslev C, et al. Genome-wide profiling of liver X receptor, retinoic acid receptor, and peroxisome proliferator-activated receptor alpha in mouse liver reveals extensive sharing of binding sites. *Mol Cell Biol.* (2012) 32:852–67. doi: 10.1128/MCB.01675-11

42. Simons SS, Edwards DP, Kumar R. Minireview: dynamic structures of nuclear hormone receptors: new promises and challenges. *Mol Endocrinol.* (2014) 28:173–82. doi: 10.1210/me.2013-1334

43. Bastien J, Rochette-Egly C. Nuclear retinoic acid receptors and the transcription of retinoid-target genes. *Gene.* (2004) 328:1–16. doi: 10.1016/j.gene.2003.12.005

44. Rochette-Egly C, Germain P. Dynamic and combinatorial control of gene expression by nuclear retinoic acid receptors (RARs). *Nucl Recept Signal.* (2009) 7:e005. doi: 10.1611/hrs.07005

45. Ide T, Shimano H, Yoshikawa T, Yahagi N, Amemiya-Kudo M, Matsuoka T, et al. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. *ILRs suppress lipid degradation gene promoters through inhibition of PPAR signaling.* *Mol Endocrinol.* (2003) 17:1255–67. doi: 10.1210/me.2003-0766

46. DiRenzo J, Soderstrom M, Kurokawa R, Ogliastro MH, Ricote M, Ingreby S, et al. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. *Mol Cell Biol.* (1997) 17:2166–76. doi: 10.1128/MCB.17.4.2166

---

Penkert et al. Vitamin A and Vaccines

9. Chaves GV, Peres WA, Gonçalves JC, Ramalho A. Vitamin A and retinol-binding protein deficiency among chronic liver disease patients. *Nutrition.* (2015) 31:664–8. doi: 10.1016/j.nut.2014.10.016

10. Quinlan KP, Hayani KC. Vitamin A and respiratory syncytial virus infection. Serum levels and supplementation trial. *Arch Pediatr Adolesc Med.* (1996) 150:25–30. doi: 10.1001/archpedi.1996.02170260029004

11. Ellison RG, Greer BP, Burney JL, Goddell LS, Bower KB, Nicklás JC, et al. Observations and conversations: home preparation of infant formula among a sample of low-income mothers in the southeastern US. *J Nutr Educ Behav.* (2017) 49:579–87 e1. doi: 10.1016/j.jneb.2017.04.027

12. Institute of Medicine, Food and Nutrition Board. *Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc.* 2001. Washington, DC: National Academy Press.
Penkert et al. Vitamin A and Vaccines

54. Kawaguchi R, Zhong M, Kassai M, Ter-Stepanian M, Sun H. Vitamin A

55. Huang Z, Liu Y, Qi G, Brand D, Zheng SG. Role of vitamin A in the immune

56. Sommer A. Vitamin a deficiency and clinical disease: an historical overview

57. Beijer MR, Molenaar R, Goverse G, Mebius RE, Kraal G, den Hae
d JM.

58. Hotspots for vitamin-steroid-thyroid hormone response elements within

59. Ross AC. Vitamin A supplementation and retinoic acid treatment in the

60. Pasatiempo AM, Taylor CE, Ross AC. Antibody production in vitamin A-depleted rats is impaired after immunization with bacterial polysaccharide or protein antigens. FASEB J. (1990) 4:2518–27. doi:10.1096/fasebj.4.8.2110538

61. Penkert RR, Iverson A, Rosch JW, Hurwitz JL. Prevnar-13 vaccine failure

62. Surman SL, Jones BG, Rudraraju R, Sealy RE, Hurwitz JL. Intranasal

63. Sun CM, Hall JA, Blank RB, Boudloux N, Oukka M, Mora JR, et al. Small intestine lamina propria dendritic cells promote de novo generation of FoxP3+ T reg cells via retinoic acid. J Exp Med. (2007) 204:1775–85. doi:10.1084/jem.20070602

64. Coombs JL, Siddiqui KR, Arancibia-Cárcamo CV, Hall J, Sun CM, Belkaid Y, et al. A functionally specialized population of mucosal CD103+ DCs induces FoxP3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med. (2007) 204:1757–64. doi:10.1084/jem.20070590

65. Ross AC. Vitamin A and retinoic acid in T cell-related immunity. Am J Clin

66. Tejón G, Manriquez V, De Calisto J, Flores-Santibáñez F, Hidalgo Y, Crisóstomo N, et al. Vitamin A impairs the reprogramming of Tregs into IL-17-producing cells during intestinal inflammation. Biomed Res Int. (2015) 2015:37893. doi:10.1155/2015/37893

67. Coombes JL, Siddiqui KR, Arancibia-Cárcamo CV, Hall J, Sun CM, Belkaid Y, et al. A functionally specialized population of mucosal CD103+ DCs induces FoxP3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med. (2007) 204:1757–64. doi:10.1084/jem.20070590

68. Ross AC. Vitamin A and retinoic acid in T cell-related immunity. Am J Clin

69. Park BV, Pan F. The role of nuclear receptors in regulation of Th17/Treg

70. Tejón G, Manriquez V, De Calisto J, Flores-Santibáñez F, Hidalgo Y, Crisóstomo N, et al. Vitamin A impairs the reprogramming of Tregs into IL-17-producing cells during intestinal inflammation. Biomed Res Int. (2015) 2015:37893. doi:10.1155/2015/37893

71. Raverdeau M, Mills KH. Modulation of T cell and innate immune responses by retinoic Acid. J Immunol. (2014) 192:2953–8. doi:10.4049/jimmunol.1303245

72. Surman SL, Jones BG, Woodland DL, Hurwitz JL. Enhanced CD103 expression and reduced frequencies of virus-specific CD8(+) T cells among airway lymphocytes after influenza vaccination of mice deficient in vitamins A + D. Viral Immunol. (2013) 30:737–43. doi:10.1089/vim.2012.0086

73. Stephensen CB, Jiang X, Freytag T. Vitamin A deficiency increases the in vivo development of IL-10-positive Th2 cells and decreases development of Th1 cells in mice. J Nutr. (2004) 134:2660–6. doi:10.1093/jn/134.10.2660

74. Spiliakas CG, Lee GR, Flavell RA. Twisting the Th1/Th2 immune response via the retinoic X receptor: lessons from a genetic approach. Eur J Immunol. (2003) 33:3404–4. doi:10.1002/eji.200335588

75. Huang Z, Liu Y, Qi G, Brand D, Zheng SG. Role of vitamin A in the immune system. J Clin Med. (2018) 7:2528. doi:10.3390/jcm7090258

76. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall

77. Boelsen LK, Dunne EM, Lamb KE, Bright K, Cheung YB, Tikoduadua L, et al. Long-term impact of pneumococcal polysaccharide vaccination on nasopharyngeal carriage in children previously vaccinated with various pneumococcal conjugate vaccine regimens. Vaccine. (2015) 33:5708–14. doi:10.1016/j.vaccine.2015.07.059

78. Greenhow TL, Hung Y, Herz A. Bacteremia in children 3 to 36 months old after introduction of conjugated pneumococcal vaccines. Pediatrics. (2017) 139.e20162098. doi:10.1542/peds.2016-2098

79. Pasatiempo AM, Taylor CE, Ross AC. Antibody production in vitamin A-depleted rats is impaired after immunization with bacterial polysaccharide or protein antigens. FASEB J. (1990) 4:2518–27. doi:10.1096/fasebj.4.8.2110538

80. Pasatiempo AM, Bowman TA, Taylor CE, Ross AC. Vitamin A depletion and repletion: effects on antibody response to the capsular polysaccharide of Streptococcus pneumoniae, type III (SSS-III). Am J Clin Nutr. (1989) 49:501–10. doi:10.1093/ajcn/49.3.501

81. Pasatiempo AM, Taylor CE, Ross AC. Vitamin A status and the immune response to pneumococcal polysaccharide: effects of age and early stages of retinol deficiency in rats. J Nutr. (1991) 121:556–62. doi:10.1093/jn/121.4.556

82. Ross AC, Vitamin A deficiency and retinoid repletion regulate the antibody response to bacterial antigens and the maintenance of natural killer cells. Clin Immunol Immunopathol. (1996) 80:563–72. doi:10.1006/ciim.1996.0143

83. Irlam JH, Visser MM, Rollins NN, Siegfried N. Micronutrient supplementation in children and adolescents with HIV infection. Cochrane Database Syst Rev. (2010) CD003650. doi:10.1002/14651858.CD003650.pub3

84. Vitamin A supplementation: who, when and how. Community Eye Health. (2013) 26:71

85. Humphrey JH, Agostina T, Wu L, Usman A, Nurachim M, Subardja D, et al. Impact of neonatal vitamin A supplementation on infant morbidity and mortality. J Pediatr. (1996) 128:489–96. doi:10.1001/s0022-3476(96)70359-1

86. Nacul LC, Kirkwood BR, Arthur P, Morris SS, Magalhães M, Fink MC. Randomised, double blind, placebo controlled clinical trial of efficacy of
vitamin A treatment in non-measles childhood pneumonia. *BMJ* (1997) 315:505–10. doi: 10.1136/bmj.315.7107.505

87. Imdad A, Mayo-Wilson E, Herzer K, Bhutta ZA. Vitamin A supplementation for preventing morbidity and mortality in children from six months to five years of age. *Cochrane Database Syst Rev.* (2017) CD008524. doi: 10.1002/14651858.CD008524.pub3

88. Mayo-Wilson E, Imdad A, Herzer K, Yakoob MY, Bhutta ZA. Vitamin A supplements for preventing mortality, illness, and blindness in children aged under 5: systematic review and meta-analysis. *BMJ* (2011) 343:d5094. doi: 10.1136/bmj.d5094

89. Sommer A, Tarwojto I, Hussaini G, Susanto D. Increased mortality in children with mild vitamin A deficiency. *Lancet.* (1983) 2:585–8. doi: 10.1016/S0140-6736(83)90977-3

90. Fawzi WW, Chalmers TC, Herrera MG, Mosteller F. Vitamin A supplementation and child mortality. *A meta-analysis. JAMA.* (1993) 269:898–903. doi: 10.1001/jama.269.7.898

91. Vitamin A supplementation in northern Ghana: effects on clinic attendances, hospital admissions, and child mortality. Ghana VAST Study Team. *Lancet.* (1993) 342:7–12. doi: 10.1016/0140-6736(93)91879-Q

92. West KP, Pokhrel RP, Katz J, LeClerq SC, Khatry SK, Shrestha SR, et al. Efficacy of vitamin A in reducing preschool child mortality in Nepal. *Lancet.* (1991) 338:67–71. doi: 10.1016/0140-6736(91)90070-6

93. D’Souza RM, D’Souza R. Vitamin A for treating measles in children. *Cochrane Database Syst Rev.* (2001) CD004179.

94. Humphrey HJ, Iliff PJ, Marinda E, Moulton LH, Chidawanyika H, et al. Effects of a single large dose of vitamin A, given during the postpartum period to HIV-positive women and their infants, on child HIV infection, HIV-free survival, and mortality. *J Infect Dis.* (2006) 193:860–71. doi: 10.1086/503066

95. Fawzi WW, Mbise RL, Hertzmark E, Fataki MR, Herrera MG, Ndossi G, et al. A randomized trial of vitamin A supplements in relation to mortality among human immunodeficiency virus-infected and uninfected children in Tanzania. *Pediatr Infect Dis J.* (1999) 18:127–33. doi: 10.1097/00002200-199902000-00009

96. Shankar AH, Benton G, Semba RD, Baisor M, Paino J, Tamia S, et al. Effect of vitamin A supplementation on morbidity due to *Plasmodium falciparum* in young children in Papua New Guinea: a randomised trial. *Lancet.* (1999) 354:203–9. doi: 10.1016/S0140-6736(98)02923-2

97. Villamor E, Fawzi WW. Effects of vitamin A supplementation on immune responses and clinical outcomes with a concurrent clinical outcome. *Clin Microbiol Rev.* (2005) 18:446–64. doi: 10.1128/CMR.18.3.446-464.2005

98. Rahman MM, Mahalanabis D, Hossain S, Wahed MA, Alvarez JO, Ober G, et al. Simultaneous vitamin A administration at routine immunization contact enhances antibody response to diphtheria vaccine in infants younger than six months. *J Nutr.* (1999) 129:2192–5. doi: 10.1093/jn/129.12.2192

99. Semba RD, Muhilal, Audet S, et al. Reduced seroconversion to measles in infants given vitamin A with measles vaccination. *Lancet.* (1995) 345:1330–2. doi: 10.1016/S0140-6736(95)92536-8

100. Semba RD, Akib A, Beeler J, Munasir Z, Permaesih D, Muheryadiantingsih, et al. Effect of vitamin A supplementation on measles vaccination in nine-month-old infants. Public Health. (1997) 111:245–7. doi: 10.1038/sj.ph.1900366

101. Bennett CS, Balde A, George E, Kidd M, Whittle H, Lisse IM, et al. Effect of vitamin A supplementation on measles-specific antibody levels in Guinea-Bissau. *Lancet.* (2002) 359:1313–4. doi: 10.1016/S0140-6736(02)08274-0

102. Bhattacharya S, Singh A. Phasing out of the universal mega dose of vitamin A prophylaxis to avoid toxicity. *AIDS Public Health.* (2017) 4:38–46. doi: 10.3934/publichealth.2017.1.38

103. Rahmathullah L, Underwood BA, Thulasiaraj RD, Milton RC, Rasamwasy K, Rahmathullah R, et al. Reduced mortality among children in southern India receiving a small weekly dose of vitamin A. *N Engl J Med.* (1990) 323:929–35. doi: 10.1056/NEJM199010043231401

104. Boldeke ME, Gelmann EP, Byers SW. Cross-regulation of signaling pathways: an example of nuclear hormone receptors and the canonical Wnt pathway. *Exp Cell Res.* (2010) 316:1763–72. doi: 10.1016/j.yexcr.2010.02.001

105. Tanner-Mendoza L, Wang TT, Lallemant B, Zrang R, Nagai Y, Bourdeau V, et al. Convergence of vitamin D and retinoic acid signalling at a common hormone response element. *EMBO Rep.* (2006) 7:180–5. doi: 10.1038/sj.embor.7400594

106. Cao X, Teitelbaum SL, Zhu HJ, Zhang L, Feng X, Ross FP. Competition for a unique response element mediates retinoic acid inhibition of vitamin D3-stimulated transcription. *J Biol Chem.* (1996) 271:20650–4. doi: 10.1074/jbc.271.34.20650

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Penkert, Rowe, Surman, Sealy, Rosch and Hurwitz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.